Glenmark Pharma Gains on Growth Outlook

  Published 9 months ago

Glenmark shares rise 3.5% as HSBC retains "buy," citing growth drivers, approvals, and strong business momentum.

  • HSBC sees easing R&D, Monroe supplies, U.S. approvals, and India launches driving Glenmark’s strong future growth.
  • Stock remains bullish above 100-day and 200-day averages, marking the strongest session gains since July 11.
  • Analyst consensus remains "buy," with a median price target of ₹2,380, implying 19% upside from current.

You might like these

ACME Solar Secures 300 MW PPA in Rajasthan

Union Bank Slips on Weak Q1

SBC Exports Secures $12.5M Garments Contract

Saudi Pharma JV Boosts Local Production

Siri Fort Auditorium Renovation Project Launched

Aurobindo Pharma Faces USFDA Observations

Wabag Wins $272M Saudi Desal Deal

News that matters the most ⚡